These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
596 related items for PubMed ID: 17433425
1. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance. Bamias A, Tsiatas ML, Kafantari E, Liakou C, Rodolakis A, Voulgaris Z, Vlahos G, Papageorgiou T, Tsitsilonis O, Bamia C, Papatheodoridis G, Politi E, Archimandritis A, Antsaklis A, Dimopoulos MA. Gynecol Oncol; 2007 Jul; 106(1):75-81. PubMed ID: 17433425 [Abstract] [Full Text] [Related]
3. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Freedman RS, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash M, Levy L, Atkinson EN, Zhang HZ, Melichar B, Patenia R, Templin S, Scott W, Platsoucas CD. Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077 [Abstract] [Full Text] [Related]
5. Decrease in intrahepatic CD56+ lymphocytes in gastric and colorectal cancer patients with liver metastases. Gulubova M, Manolova I, Kyurkchiev D, Julianov A, Altunkova I. APMIS; 2009 Dec; 117(12):870-9. PubMed ID: 20078551 [Abstract] [Full Text] [Related]
9. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Giuntoli RL, Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow RE, Oelke M. Anticancer Res; 2009 Aug; 29(8):2875-84. PubMed ID: 19661290 [Abstract] [Full Text] [Related]
10. Increased frequency of CD4+ cells expressing CD161 in cancer patients. Iliopoulou EG, Karamouzis MV, Missitzis I, Ardavanis A, Sotiriadou NN, Baxevanis CN, Rigatos G, Papamichail M, Perez SA. Clin Cancer Res; 2006 Dec 01; 12(23):6901-9. PubMed ID: 17145807 [Abstract] [Full Text] [Related]
12. CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression. Shen LS, Wang J, Shen DF, Yuan XL, Dong P, Li MX, Xue J, Zhang FM, Ge HL, Xu D. Clin Immunol; 2009 Apr 01; 131(1):109-18. PubMed ID: 19153062 [Abstract] [Full Text] [Related]
13. Lymphocyte recovery in advanced ovarian cancer patients after high-dose chemotherapy and peripheral blood stem cell plus growth factor support: clinical implications. Ferrandina G, Pierelli L, Perillo A, Rutella S, Ludovisi M, Leone G, Mancuso S, Scambia G. Clin Cancer Res; 2003 Jan 01; 9(1):195-200. PubMed ID: 12538469 [Abstract] [Full Text] [Related]
14. The correlation between the percent of CD3- CD56+ cells and NK precursor function. Gharehbaghian A, Donaldson C, Newman J, Bannister G, Bradley BA. Iran J Allergy Asthma Immunol; 2006 Dec 01; 5(4):167-75. PubMed ID: 17237569 [Abstract] [Full Text] [Related]
16. Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast. Leong PP, Mohammad R, Ibrahim N, Ithnin H, Abdullah M, Davis WC, Seow HF. Immunol Lett; 2006 Feb 15; 102(2):229-36. PubMed ID: 16246429 [Abstract] [Full Text] [Related]
20. [Detection of lymphocyte subsets in the peripheral blood of patients with malignant ovarian tumors]. Liu M, Xie J, Zhao S. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun 15; 30(6):627-9, 634. PubMed ID: 24909286 [Abstract] [Full Text] [Related] Page: [Next] [New Search]